Daiichi Sankyo (DSNKY) Expected to Post Quarterly Earnings on Friday

Key Points

• Daiichi Sankyo is expected to report quarterly results after the market closes on Friday, October 30. Analysts forecast earnings of $0.21 per share on $3.59 billion in revenue, while full-year EPS guidance is set at $0.87.
• In the prior quarter, the company earned $0.24 per share, slightly below estimates, but revenue of $3.61 billion exceeded expectations. Analysts project fiscal-year EPS of $0.93 and next-year EPS of $1.08.
• Analyst sentiment is cautious: Jefferies downgraded the stock to “hold,” Zacks Research cut it to “strong sell,” and the consensus rating is “Reduce.” Shares recently traded at $18.11, well below the 52-week high of $26.86.

Daiichi Sankyo (OTCMKTS:DSNKY - Get Free Report) will likely be issuing its results after the market closes on Friday, October 30th. Analysts expect the company to post earnings of $0.21 per share and revenue of $3.59 billion for the quarter. Daiichi Sankyo has set its FY 2026 guidance at 0.870-0.870 EPS.

Daiichi Sankyo (OTCMKTS:DSNKY - Get Free Report) last issued its earnings results on Friday, July 31st. The company reported $0.24 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.25 by ($0.01). The company had revenue of $3.61 billion for the quarter, compared to analysts' expectations of $3.32 billion. Daiichi Sankyo had a net margin of 10.92% and a return on equity of 14.35%. On average, analysts expect Daiichi Sankyo to post $0.93 EPS for the current fiscal year and $1.08 EPS for the next fiscal year.

Daiichi Sankyo Price Performance

Daiichi Sankyo stock opened at $18.11 on Friday. The stock has a market cap of $33.74 billion, a price-to-earnings ratio of 21.06, a price-to-earnings-growth ratio of 1.91 and a beta of -0.11. The company has a debt-to-equity ratio of 0.29, a current ratio of 2.92 and a quick ratio of 1.96. Daiichi Sankyo has a 1 year low of $14.98 and a 1 year high of $26.86. The firm has a 50-day moving average of $17.81 and a two-hundred day moving average of $17.16.

Analyst Upgrades and Downgrades

DSNKY has been the topic of several research analyst reports. Jefferies Financial Group cut Daiichi Sankyo from a "buy" rating to a "hold" rating in a research note on Thursday, July 30th. Zacks Research lowered Daiichi Sankyo from a "hold" rating to a "strong sell" rating in a research report on Tuesday. One investment analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of "Reduce".

About Daiichi Sankyo

Daiichi Sankyo Co, Ltd. is a Japan-based global pharmaceutical company that researches, develops, manufactures and markets prescription medicines. The company focuses primarily on oncology, with additional activities in areas such as cardiovascular disease, rare diseases and other specialty therapies. Its products are marketed in Japan and internationally through subsidiaries, partnerships and licensing agreements.

Daiichi Sankyo is particularly known for its antibody-drug conjugate technology, which is designed to deliver cancer-killing agents more selectively to tumor cells.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.